###begin article-title 0
###xml 72 78 <span type="species:ncbi:9606">Humans</span>
Lipoprotein Genotype and Conserved Pathway for Exceptional Longevity in Humans
###end article-title 0
###begin article-title 1
The Key to Longevity? Having Long-Lived Parents Is a Good Start
###end article-title 1
###begin p 2
###xml 351 352 351 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 379 380 379 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 434 435 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 798 803 798 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 909 910 909 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 924 925 924 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1397 1398 1397 1398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1431 1436 1431 1436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 154 160 <span type="species:ncbi:9606">humans</span>
###xml 1716 1722 <span type="species:ncbi:9606">humans</span>
Alteration of single genes involved in nutrient and lipoprotein metabolism increases longevity in several animal models. Because exceptional longevity in humans is familial, it is likely that polymorphisms in genes favorably influence certain phenotypes and increase the likelihood of exceptional longevity. A group of Ashkenazi Jewish centenarians ( n = 213), their offspring ( n = 216), and an age-matched Ashkenazi control group ( n = 258) were genotyped for 66 polymorphisms in 36 candidate genes related to cardiovascular disease (CVD). These genes were tested for association with serum lipoprotein levels and particle sizes, apolipoprotein A1, B, and C-3 levels and with outcomes of hypertension, insulin resistance, and mortality. The prevalence of homozygosity for the -641C allele in the APOC3 promoter (rs2542052) was higher in centenarians (25%) and their offspring (20%) than in controls (10%) ( p = 0.0001 and p = 0.001, respectively). This genotype was associated with significantly lower serum levels of APOC3 and a favorable pattern of lipoprotein levels and sizes. We found a lower prevalence of hypertension and greater insulin sensitivity in the -641C homozygotes, suggesting a protective effect against CVD and the metabolic syndrome. Finally, in a prospectively studied cohort, a significant survival advantage was demonstrated in those with the favorable -641C homozygote ( p < 0.0001). Homozygosity for the APOC3 -641C allele is associated with a favorable lipoprotein profile, cardiovascular health, insulin sensitivity, and longevity. Because modulation of lipoproteins is also seen in genetically altered longevity models, it may be a common pathway influencing lifespan from nematodes to humans.
###end p 2
###begin p 3
###xml 105 111 <span type="species:ncbi:9606">humans</span>
An allele of apolipoprotein C3 (which regulates lipoprotein metabolism) is more prevalent in centenarian humans than controls. This genotype is associated with a favorable lipoprotein profile, cardiovascular health, insulin sensitivity, and longevity.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 360 361 360 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b001">1</xref>
###xml 494 495 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b002">2</xref>
###xml 497 498 497 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b003">3</xref>
###xml 741 742 741 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b004">4</xref>
###xml 968 969 968 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b005">5</xref>
###xml 165 171 <span type="species:ncbi:9606">humans</span>
Manipulation of single genes can confer longevity in lower organisms, supporting the notion that understanding pathways for exceptional longevity may be possible in humans. Because the contribution of genetics to lifespan is estimated to be only  20%, a way to enhance the odds of identifying genetic factors is to study those with very exceptional survival [ 1]. Favorable modulation of aging processes and disease susceptibility is strongly inherited in families with exceptional longevity [ 2, 3]. Current centenarians have survived to more than double their life expectancy at birth, and have often been spared from age-related diseases, specifically cardiovascular disease (CVD), Alzheimer disease, diabetes mellitus (DM), and cancer [ 4]. Furthermore, evidence suggests that the offspring of centenarians may inherit protection against major causes of mortality, because they have approximately 50% lower prevalence of these major diseases than control groups [ 5].
###end p 5
###begin p 6
###xml 1271 1272 1271 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b006">6</xref>
###xml 638 650 <span type="species:ncbi:9606">participants</span>
Because of the strong heritability of this survival advantage, we began a search for gene variants that could explain the extended life of centenarians and their families among a genetically homogeneous population of Ashkenazi Jews. Crucial to our approach is the knowledge that only 1/10,000 survives to 100 y, while the average lifespan in the US is  77 y. Thus, enrichment in the frequency of certain gene variants at extreme old age probably reflects a selection effect that increases the likelihood of survival. Here we test if polymorphisms in certain candidate genes are significantly more frequent in centenarians than in younger participants. Given that the extreme old age of the probands precludes the use of a proper age-matched control group for analysis of traits that may be related to exceptional longevity, (e.g., lipoprotein levels), we also recruited their offspring, many of whom presumably inherited longevity gene variants and thus should also manifest the longevity phenotype. We reasoned that this approach would permit comparison of the offspring to age-matched controls who would not be expected to be enriched with longevity gene variants, thereby accounting for period and cohort effects and phenotypic variation that may occur at older age [ 6].
###end p 6
###begin p 7
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b006">6</xref>
###xml 404 410 404 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(CETP)</italic>
###xml 642 643 642 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b007">7</xref>
###xml 709 717 709 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(APOC3),</italic>
###xml 773 778 <span type="species:ncbi:9606">human</span>
We recently reported that lipoprotein particle sizes are increased in centenarians and their offspring, and suggested that this trait may increase the likelihood of attaining exceptional longevity [ 6]. This phenotype was also associated with approximately a 3-fold increased frequency of homozygosity (valine-valine [VV]) of a common functional variant (I405V) in the cholesterol ester transfer protein (CETP) gene, and decreased CETP levels. Further, through a genome-wide scan, Geesaman and coworkers found increased frequency of polymorphisms in the microsomal transfer protein in centenarian sibling pairs but not in other populations [ 7]. Here we implicate a polymorphism in the apolipoprotein C3 gene (APOC3), yet another gene regulating lipoprotein metabolism, in human longevity. We further report association of this same polymorphism with decreased serum apolipoprotein C3 (APOC3) levels, and favorable lipoprotein profile, outcomes of age-related disease, and lifespan.
###end p 7
###begin title 8
Results
###end title 8
###begin p 9
###xml 559 564 559 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 569 573 569 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP</italic>
###xml 576 584 576 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040113-g001">Figure 1</xref>
###xml 619 620 619 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 728 733 725 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 819 820 813 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 856 860 850 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP</italic>
###xml 935 940 929 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 1052 1053 1046 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1067 1068 1061 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1117 1122 1111 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 1139 1143 1133 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP</italic>
###xml 1146 1154 1140 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040113-g002">Figure 2</xref>
###xml 1240 1245 1234 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 1336 1337 1330 1331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1354 1362 1348 1356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040113-g003">Figure 3</xref>
We reasoned that due to selective mortality, favorable genotypes will be present at higher frequency among centenarians than in younger controls. We studied 66 single nucleotide polymorphisms (SNP) in 36 candidate genes in pathways related to lipoprotein metabolism and other risk factors for CVD. After applying the Bonferroni correction for multiple comparisons, two of the associations with exceptional longevity remained statistically significant. Analysis of the frequency trend with age (in centenarian and control groups combined) for polymorphisms in APOC3 and CETP ( Figure 1), revealed a highly significant ( p < 0.0006; beta = 1.89 [95% CI, 0.2-3.6]) monotonically increasing frequency trend for homozygosity for the APOC3 -641 C allele (CC)(rs2542052), and near-significance (beta = 3.06 [95% CI, 0.33-5.8, p = 0.069]) for homozygosity for the CETP codon 405 valine allele (VV)(rs5882). The CC genotype at position -641 of APOC3 had a prevalence of 25% among the centenarians and 20% in their offspring compared with only 10% in controls ( p = 0.0001 and p = 0.001, respectively). Five additional SNPs in APOC3 and six SNPs in CETP ( Figure 2) showed no evidence of association with longevity. Conversely, the prevalence of the APOC3 AA genotype was reduced in both centenarians and their offspring compared with controls ( p = 0.001 both) ( Figure 3A).
###end p 9
###begin p 10
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP</italic>
###xml 168 169 168 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 180 188 180 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040113-g002">Figure 2</xref>
###xml 403 404 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 479 486 479 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(APOA4)</italic>
###xml 509 516 509 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(APOC3)</italic>
###xml 558 566 558 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040113-g002">Figure 2</xref>
###xml 570 571 570 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b008">8</xref>
###xml 664 669 664 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA4</italic>
###xml 687 692 687 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 794 795 794 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 801 803 801 803 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 952 953 952 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 959 962 959 962 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;10</sup>
###xml 1020 1025 1020 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 1027 1032 1027 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA4</italic>
###xml 1209 1214 1209 1214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 1256 1257 1256 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1352 1360 1352 1360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3 CC</italic>
Linkage disequilibrium (LD) analysis of the CETP gene revealed that the single nucleotide polymorphism rs1800776 was in LD with rs1800775 just 2 bp apart (D' = 0.94; r 2 = 0.20) ( Figure 2). Haplotype analysis with these two SNP revealed that the C-A haplotype was statistically significantly more prevalent among individuals in the control group compared with centenarian probands (0.355 versus 0.278, p <0.004). LD analysis revealed LD across the neighboring apolipoprotein A4 (APOA4) and apolipoprotein C3 (APOC3) genes as previously reported by others ( Figure 2) [ 8]. In haplotype analysis, the prevalence of the A-C haplotype (corresponding to SNP rs675 in APOA4 and rs2542052 in APOC3) was significantly higher among the centenarian probands compared with controls (0.498 versus 0.344, p < 10 -8). The prevalence of the A-A haplotype of the same SNPs was significantly higher among the control group compared with probands (0.483 versus 0.307, p < 10 -10). Association analysis between various haplotypes of the APOC3/ APOA4 and lipid profile was not significant, neither when the most prevalent haplotypes in the two groups were compared, (CA versus AA) nor the haplotypes that contain the favorable APOC3 allele. The only trend for association ( p < 0.07) between haplotype and lipoprotein was for LDL. This suggests that the single genotype APOC3 CC is more prominent in the phenotypes.
###end p 10
###begin p 11
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP</italic>
###xml 301 306 301 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 466 467 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 719 720 719 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 754 762 754 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040113-g003">Figure 3</xref>
###xml 261 273 <span type="species:ncbi:9606">participants</span>
APOC3 and CETP encode gene products involved in lipoprotein metabolism and thus the favorable alleles showing monotonic increases in allele frequencies among older age strata would also be expected to be associated with a favorable lipoprotein profile. Indeed, participants of all groups carrying the APOC3 -641 CC genotype had lower serum levels of APOC3 compared with those carrying either CA or AA (CA/AA) genotype (mean [SE]: 10.1 [1.1] versus 13.2 [1.1] mg/dl, p < 0.05). Given the higher prevalence of this genotype in centenarians, it is therefore not surprising that serum levels of APOC3 were lower in centenarians and their offspring than in controls (mean [SE]: 9.8 [0.6], 9.3 [0.5] versus 11.7 [0.7] mg/dl; p < 0.05 and 0.01, respectively) ( Figure 3B).
###end p 11
###begin p 12
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 87 94 87 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0040113-t001">Table 1</xref>
###xml 220 221 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 244 245 244 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 805 812 805 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0040113-t001">Table 1</xref>
###xml 903 911 903 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3 CC</italic>
###xml 635 638 <span type="species:ncbi:9606">men</span>
Relationships between other lipoprotein traits and APOC3 -641 CC genotype are shown in Table 1. Due to the dependency of lipoprotein traits on age and their modifiability with medications, we only considered offspring ( n = 131) and controls ( n = 126) not using lipid lowering drugs in this analysis. In females, triglycerides (TG), high density lipoprotein cholesterol (HDL), and their ratio, as well as low density lipoprotein cholesterol (LDL) lipoprotein particle size were significantly more favorable among those with the CC genotype compared to the CA/AA genotypes. The same trends were observed in most of the associations in men. Since there was no significant interaction between gender and genotypes, we present also the combined group of females and males and their significance. As shown in Table 1 the combined group also exhibited significant associations with lipoproteins according to APOC3 CC genotype.
###end p 12
###begin p 13
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b009">9</xref>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b010">10</xref>
###xml 199 204 199 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 312 313 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 346 354 346 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040113-g004">Figure 4</xref>
Given that insulin resistance is associated with lipid abnormalities, CVD, and death in the elderly [ 9], we estimated insulin sensitivity using the homeostatic model assessment [ 10]. The favorable APOC3 -641 CC genotype was associated with greater insulin sensitivity in the combined offspring/control group ( p < 0.05, both male and female) ( Figure 4A).
###end p 13
###begin p 14
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b011">11</xref>
###xml 407 412 407 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 470 471 470 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 482 490 482 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040113-g004">Figure 4</xref>
###xml 704 712 704 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3 CC</italic>
###xml 779 787 779 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3 CC</italic>
###xml 845 846 845 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 885 890 885 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 138 150 <span type="species:ncbi:9606">participants</span>
###xml 596 608 <span type="species:ncbi:9606">participants</span>
###xml 753 765 <span type="species:ncbi:9606">participants</span>
The most prevalent CVD marker in an aging population is progressive increase in blood pressure. Therefore, this trait was examined in our participants as a surrogate for vascular aging. The prevalence of hypertension (as defined in the VII Report of the Joint National Commission on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) [ 11] was significantly lower among those with the APOC3 -641 CC genotype than among those with CA/AA genotypes ( p = 0.04) ( Figure 4B). Since existing CVD can lead to reductions in blood pressure, we repeated the test after excluding all participants with CVD from the analysis. Still, hypertension was less prevalent in those with the favorable APOC3 CC genotype (prevalence of hypertension in participants carrying the APOC3 CC genotype was 28.6% compared with 44% in the CA/AA group, p = 0.026). Other known variants of the APOC3 gene: C(-482)T, T(-455)C, C1100T, C3175G, and T3206G, (rs2854117, rs2854116, rs4520, rs5128, and rs4225, respectively) were not associated with TG levels, insulin sensitivity, or blood pressure.
###end p 14
###begin p 15
###xml 216 221 216 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 233 241 233 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0040113-g005">Figure 5</xref>
###xml 308 309 308 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 11 23 <span type="species:ncbi:9606">participants</span>
###xml 200 212 <span type="species:ncbi:9606">participants</span>
Of the 381 participants we have genotyped since 1998, 64 had the CC genotype. To describe the relationship between genotype and death, we plotted the Kaplan-Meier survival function estimates of study participants by APOC3 genotype ( Figure 5). Survival was significantly greater among CC genotype carriers ( p = 0.0007).
###end p 15
###begin title 16
Discussion
###end title 16
###begin p 17
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b008">8</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b012">12</xref>
###xml 317 322 317 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b013">13</xref>
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b017">17</xref>
###xml 951 953 951 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b019">19</xref>
###xml 1010 1012 1010 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b020">20</xref>
###xml 1066 1071 1066 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 1128 1130 1128 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b021">21</xref>
###xml 1132 1134 1132 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b022">22</xref>
###xml 1363 1368 1363 1368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 1431 1433 1431 1433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b023">23</xref>
###xml 1436 1441 1436 1441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 1520 1522 1520 1522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b024">24</xref>
###xml 1583 1585 1583 1585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b025">25</xref>
###xml 749 752 <span type="species:ncbi:9606">men</span>
###xml 760 768 <span type="species:ncbi:9606">patients</span>
###xml 963 971 <span type="species:ncbi:9606">patients</span>
###xml 1307 1313 <span type="species:ncbi:10090">Murine</span>
###xml 1357 1362 <span type="species:ncbi:9606">human</span>
###xml 1451 1455 <span type="species:ncbi:10090">mice</span>
APOC3 is a major component of very low density lipoproteins and chylomicron remnants; it is also a minor component of HDL [ 8]. In vitro, it has been shown to inhibit the activity of lipoprotein lipase, resulting in delayed TG clearance from plasma [ 12]. Several studies have shown that various polymorphisms of the APOC3 gene either within the promoter region, in particular the T-455C variant polymorphism in the insulin response element, or in the gene, are associated with elevated TG levels but not with significant change in APOC3 levels [ 13- 17]. Previous studies have also associated high levels of APOC3 with macrovascular and microvascular disease and their risks. Increased APOC3 levels were a significant indicator of coronary risk in men and in patients with metabolic syndrome. In particular, those with vascular disease and metabolic syndrome had a markedly increased probability of coronary heart disease in an allele-specific way [ 19], and in patients with type 2 diabetes predisposition [ 20]. While few studies have correlated both unfavorable APOC3 promoter genotypes and high APOC3 levels with outcome [ 21, 22], our study is the first to our knowledge to implicate a genotype with low levels of APOC3 and a favorable lipid phenotype with better outcomes related to longer lifespan. Murine models expressing one to 100 copies of the human APOC3 gene had high levels of APOC3 and were hypertriglyceridemic [ 23]. APOC3 knockout mice show absent or decreased APOC3 protein with reduced TG levels [ 24], even in the presence of streptozotocin-induced diabetes [ 25]. The impact on lifespan has not, however, been determined in these models.
###end p 17
###begin p 18
###xml 245 250 245 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 50 56 <span type="species:ncbi:9606">people</span>
We hypothesized that since only one out of 10,000 people in the general population has survived to 100 y, there should be potent enrichment for favorable genotypes in this unique population. The monotonic, progressive over-representation of the APOC3 -641 CC genotype with increasing age, from a relatively infrequent 10% at age  60 y to 25% in individuals surviving to age  100 y is statistically robust and provides evidence that this genotype provides a selective advantage for survival to exceptional old age. Underlying population stratification could be responsible for genotypic associations detected in case-control studies, but this is much less likely in this relatively homogeneous Ashkenazi population. Furthermore, we demonstrated association of this same genotype with survival in a prospectively followed cohort. Finally, the prevalence of heterozygosity for recessive disease alleles (nearly) unique to the Ashkenazi population, e.g., breast cancer and Tay-Sachs disease, did not differ significantly between longevity cases and controls, suggesting the lack of population stratification (unpublished data).
###end p 18
###begin p 19
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 342 347 342 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 603 608 603 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 310 322 <span type="species:ncbi:9606">participants</span>
###xml 435 447 <span type="species:ncbi:9606">participants</span>
In addition to showing statistical associations of the APOC3 genotype with exceptional longevity, we found significant associations between this genotype and several intermediate longevity-associated traits directly related to lipoproteins. First, serum APOC3 levels were significantly ( 30%) decreased in our participants with the favorable APOC3 genotype. Second, lipid profiles were altered in the expected (favorable) direction in participants with this genotype. Finally, this favorable genotype was associated with reduced insulin resistance and less hypertension. These findings suggest that the APOC3 genotype may have favorable pleiotrophic effects on a number of cardiovascular traits and mortality.
###end p 19
###begin p 20
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b022">22</xref>
Interestingly, while a recent study found that the phenotypic effects of APOC3 polymorphisms are modified by dietary polyunsaturated fatty acids [ 22], the interactions of APOC3 levels with exercise, body mass index or other environmental effect have not been well studied. Our population by genotype had similar body mass index, suggesting that body weight is not strongly modulated by genotype.
###end p 20
###begin p 21
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b008">8</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b026">26</xref>
###xml 127 142 127 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APO A1-C3-A4-A5</italic>
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b008">8</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b027">27</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b028">28</xref>
###xml 480 485 480 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
The APOC3 gene is located on the long arm of Chromosome 11q23, in tandem with the apolipoprotein A1 and A4 genes [ 8, 26]. The APO A1-C3-A4-A5 gene cluster has been studied extensively in relation to lipoproteins and CVD, and most recently in the oldest old [ 8, 27, 28]. Given LD within this gene cluster, we cannot rule out the possibility that the associations we have demonstrated may be due to other functional SNP within this gene cluster. However, our observation that the APOC3 -641 CC genotype associates with APOC3 levels suggests that this is a functional SNP or is marking a functional SNP within this gene. Further functional studies will be required to determine if this promoter variant directly results in a decrease in transcription.
###end p 21
###begin p 22
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA4</italic>
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3.</italic>
###xml 393 394 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b008">8</xref>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b027">27</xref>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b028">28</xref>
###xml 650 655 650 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
Our haplotype analysis revealed a 2-SNP haplotype spanning both APOA4 and APOC3. One haplotype, AA in SNPs (rs675 and rs2542052, respectively), was found to be significantly more prevalent among controls, whereas the AC haplotype was significantly more prevalent among centenarians. The association between these two genes and plasma lipids levels in populations has been reported elsewhere [ 8, 27, 28]. Thus, sequence variants in partial LD that constitute one or more haplotypes across more than one of these apolipoprotein genes may influence longevity. However, our findings that Apolipoprotein A1 and Apolipoprotein B levels are not altered by APOC3 genotype, suggest that the effect of the genotype on the lipoprotein phenotype is mainly mediated by mechanisms that do not involve alterations of these apolipoproteins.
###end p 22
###begin p 23
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 181 186 181 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b029">29</xref>
###xml 318 323 318 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b030">30</xref>
###xml 483 488 483 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 701 706 701 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
We have also shown an association of the APOC3 -641 CC genotype with increased insulin sensitivity as measured by homeostatic model assessment. There are known polymorphisms of the APOC3 promoter within an insulin response element that affect the level of transcription in response to insulin in vitro [ 29]. In vivo, APOC3 transcription seems to be dependant on insulin, among other factors [ 30]. Although the -641 variant is not located within the insulin response element of the APOC3 gene, the favorable CC genotype was strongly associated with a better insulin sensitivity estimated by the homeostatic model assessment. This can potentially contribute to healthier aging in individuals with the APOC3 -641 CC genotype.
###end p 23
###begin p 24
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b031">31</xref>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b032">32</xref>
###xml 446 450 446 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP</italic>
###xml 458 459 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b006">6</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b032">32</xref>
###xml 615 619 615 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP</italic>
###xml 658 659 658 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b006">6</xref>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b031">31</xref>
###xml 833 834 833 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b007">7</xref>
###xml 853 858 853 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 933 934 933 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</italic>
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 196 202 <span type="species:ncbi:9606">humans</span>
While the potential genetic pathways underlying human exceptional longevity remain largely unknown, pathways involved in lipoprotein metabolism appear to have important influences on longevity in humans. First, the CVD-protective phenotypes of high HDL and large lipoprotein particles sizes are dramatically expressed in our centenarians, and were confirmed in Japanese centenarians [ 31], and oldest old Italians [ 32]. Second, a variant in the CETP gene [ 6] is over-represented in our centenarians, a finding that was confirmed in oldest old Italians [ 32]. Low CETP levels, which were explained in part by this CETP variant, were observed in our study [ 6] and in Japanese centenarians [ 31]. Sequence variants in another lipoprotein gene, the microsomal transfer protein gene, were implicated in another study of centenarians [ 7]. This study adds APOC3 to the list of lipoprotein genes that may influence exceptional longevity . Interestingly, all these genes are involved in different steps of lipoprotein metabolism and could potentially be additive in their effects.
###end p 24
###begin p 25
###xml 365 371 365 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">daf-16</italic>
###xml 400 405 400 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">daf-2</italic>
###xml 568 570 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b033">33</xref>
###xml 691 693 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b034">34</xref>
###xml 776 782 776 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(vit-2</italic>
###xml 787 793 787 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vit-5)</italic>
###xml 828 830 828 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b035">35</xref>
###xml 999 1001 999 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b036">36</xref>
###xml 1179 1180 1179 1180 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</bold>
###xml 1219 1224 1219 1224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 1255 1264 1255 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(FOXO-1),</italic>
###xml 1328 1330 1328 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b029">29</xref>
###xml 1332 1334 1332 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b030">30</xref>
###xml 1376 1382 1376 1382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">daf-16</italic>
###xml 1385 1387 1385 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b033">33</xref>
###xml 1389 1391 1389 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b037">37</xref>
###xml 1410 1416 1410 1416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FOXO-1</italic>
###xml 1516 1522 1516 1522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3,</italic>
###xml 1570 1576 1570 1576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FOXO-1</italic>
###xml 1605 1607 1605 1607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b038">38</xref>
###xml 279 285 <span type="species:ncbi:9606">humans</span>
###xml 684 688 <span type="species:ncbi:10090">mice</span>
###xml 884 893 <span type="species:ncbi:7460">honeybees</span>
###xml 1172 1178 <span type="species:ncbi:9606">humans</span>
###xml 1433 1438 <span type="species:ncbi:10090">mouse</span>
While the concept that alteration of gene expression or function of a particular gene can alter lifespan has been demonstrated convincingly in lower animal models, it is important to determine if those same genes and mechanisms are relevant to the complex biology of mammals and humans. Evidence to support such a connection are the findings that abnormal nematode daf-16 (a transcription factor) or daf-2 (insulin/IGF-1 receptor homolog) causes juvenile animals to enter a state of diapause, called dauer, instead of achieving adulthood, thereby extending lifespan [ 33]. Both of these genes are part of the insulin-IGF-I signaling pathway, which has been implicated in longevity in mice [ 34]. Notably the expression of vitellogenin (yolk protein/apolipoprotein-like) genes (vit-2 and vit-5) decreases as lifespan increases [ 35]. This hypothesis has been independently examined in honeybees where the vitellogenin lipoprotein is associated with both modulation of immune function and longevity [ 36]. We suggest that modulation of apolipoprotein expression could represent one conserved mechanism of life extension influencing lifespan across species from nematodes to humans . Furthermore, one of the regulators of APOC3 expression is Forkhead Box O1 (FOXO-1), a forkhead transcription factor that mediates insulin action [ 29, 30], which is the homolog of the nematode's daf-16 [ 33, 37]. Deletion of the FOXO-1 binding site in mouse hepatocytes annuls the inhibitory action of insulin on hepatic expression of APOC3, and animals that constitutively express active FOXO-1 have hypertriglyceridemia [ 38]. Whether this example is relevant to longevity of mammalian models is not known.
###end p 25
###begin p 26
###xml 24 29 <span type="species:ncbi:9606">human</span>
Genetic determinants of human longevity are likely to be multifactorial and polygenic. Thus, polymorphisms in apolipoproteins and related genes are likely to be only one of several potential pathways in which genetic variants influence longevity. Our approach-to exploit the potent selection of favorable genotypes in exceptionally aged individuals-can be extended to other candidate genes as well as genome-wide analysis. Replications of observed associations of genotypes with longevity, coupled with functional studies to define the mechanisms whereby specific genotypes influence longevity-associated phenotypes, will provide important new understandings of killing diseases and the aging process. These new understandings could potentially provide insights into preventive and therapeutic interventions for several age-related diseases that impart significant morbidity and mortality among elderly individuals.
###end p 26
###begin title 27
Materials and Methods
###end title 27
###begin title 28
###xml 17 29 <span type="species:ncbi:9606">participants</span>
Study design and participants
###end title 28
###begin p 29
###xml 83 84 83 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b005">5</xref>
###xml 86 87 86 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b006">6</xref>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b039">39</xref>
###xml 529 639 529 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">breast cancer gene 1, breast cancer gene 2, adenomatosis polyposis coli gene, hereditary prostrate cancer gene</italic>
###xml 755 757 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b040">40</xref>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b044">44</xref>
###xml 892 894 892 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b045">45</xref>
###xml 896 898 896 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b046">46</xref>
In this case-control study, Ashkenazi Jews were recruited as described elsewhere [ 5, 6]. The Ashkenazi population is believed to have descended from a small group of founders based on both historical records and modern genetic evidence. The advantage of using founder populations is that the genetic determinants of a particular disease may be more homogeneous and easier to define, and false positive results due to population stratification is less likely [ 39]. Indeed, specific mutations in a number of disease genes (e.g., breast cancer gene 1, breast cancer gene 2, adenomatosis polyposis coli gene, hereditary prostrate cancer gene) have been initially identified in the Ashkenazi population at prevalence rates consistent with a founder effect [ 40- 44]. Stratification in these studies has not been required, and indeed these genes were later implicated in other populations, too [ 45, 46].
###end p 29
###begin p 30
###xml 967 969 967 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b047">47</xref>
###xml 210 222 <span type="species:ncbi:9606">participants</span>
###xml 546 551 <span type="species:ncbi:9606">child</span>
###xml 722 734 <span type="species:ncbi:9606">participants</span>
###xml 912 924 <span type="species:ncbi:9606">participants</span>
###xml 1005 1017 <span type="species:ncbi:9606">participants</span>
Two hundred and thirteen probands with exceptional longevity (157 females and 56 males, age 98.2 (0.36) y [mean (SE)], range 95-107 y; 48% over the age of 100 y) were recruited to participate in the study. The participants' ages were defined by birth certificates or dates of birth as stated on passports. Probands were required to have been living independently when they were 95 y of age as a reflection of good health, although at the time of recruitment they could be at any level of dependency. In addition, probands were required to have a child who was willing to participate in the study. The offspring group consisted of 122 females and 94 males (age 68.3 [0.45] y, range 51-89 y). The control group included 258 participants derived from two sources: Ashkenazi Jews from the general population recruited by the Einstein Aging Study and spouses of the recruited offspring. The study sample included 183 participants with mean age 71.3 (0.67) y, 57% female [ 47]. Spouses of offspring included 75 participants with mean age 70.2 (1.17) y, 53% female. These controls as a comparison group similar in age to the offspring are important to overcome the limitation of a cross-sectional sample, because the effects of age on genotype, phenotype (APOC3 levels, lipids etc.), and outcomes (hypertension and longevity) are minimized. Written informed consent was obtained and the study was approved by the Committee on Clinical Investigations of the Albert Einstein College of Medicine.
###end p 30
###begin title 31
Clinical evaluation
###end title 31
###begin p 32
###xml 350 351 350 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b005">5</xref>
###xml 353 354 353 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b006">6</xref>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b011">11</xref>
###xml 38 50 <span type="species:ncbi:9606">participants</span>
###xml 487 494 <span type="species:ncbi:9606">patient</span>
A research nurse visited the research participants in the morning to obtain a medical history, perform a physical examination, and draw a fasting venous blood sample. Standardized health histories were obtained using a questionnaire. At that visit, the offspring and the participating spouses underwent similar evaluations, as previously described [ 5, 6]. Systolic (first phase) and diastolic (fifth phase) blood pressure were obtained twice, using a standard sphygmomanometer with the patient sitting for at least five minutes, and hypertension was defined according to Joint National Commission VII guidelines [ 11]. EAS controls underwent a similar evaluation in an outpatient research center at our institution. All blood samples for centenarians, offspring, and controls were processed at the General Clinical Research Center at Albert Einstein College of Medicine, at the clinical laboratories of Montefiore Medical Center Laboratories (Albert Einstein College of Medicine, Bronx, New York, United States), and at LipoScience (Raleigh, North Carolina, Unites States).
###end p 32
###begin title 33
Lipids and lipoproteins
###end title 33
###begin p 34
###xml 93 105 <span type="species:ncbi:9606">participants</span>
###xml 281 286 <span type="species:ncbi:9606">human</span>
Total plasma cholesterol, TG, HDL, LDL, APOA1, and apolipoprotein B concentrations for study participants were measured by standard automated methods at the clinical laboratories of Montefiore Medical Center (coefficient of variance [CV] ranged 2.5%-3.5%). APOC3 concentrations in human serum were measured by ELISA using a commercially available kit (Wako Chemicals USA, Richmond, Virginia, United States) (CV ranged 2%-5%).
###end p 34
###begin p 35
###xml 318 319 318 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b006">6</xref>
###xml 76 88 <span type="species:ncbi:9606">participants</span>
LDL and HDL subclass levels and mean particle sizes were determined for all participants by proton nuclear magnetic resonance spectroscopy at LipoScience. Each nuclear magnetic resonance measurement produces the concentrations of three LDL subclasses and five HDL subclasses of varying size, as previously described [ 6] (CV ranged between 3.3 and 5.4). Insulin levels were measured by polyclonal immunoassay at the Hormone Assay Core of the Diabetes Research and Training Center of the Albert Einstein College of Medicine (CV of 8.4%).
###end p 35
###begin title 36
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
APOC3 genotyping
###end title 36
###begin p 37
###xml 99 104 99 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 657 659 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b048">48</xref>
A multilocus polymerase chain reaction-based assay was utilized to genotype known polymorphisms of APOC3 on Chromosome 11q: C(-641)A, C(-482)T, T(-455)C, C1100T, C3175G, T3206G. Briefly, DNA was amplified using multiplex reaction containing biotinylated primer pairs. Amplified fragments within each polymerase chain reaction product pool were then detected colorimetrically with sequence-specific oligonucleotide probes immobilized in a linear array on nylon membranes strips. Probe specificities had previously been confirmed by sequencing and by use of DNA genotyped independently through other methods such as restriction length polymorphism analysis [ 48].
###end p 37
###begin title 38
Statistical analyses
###end title 38
###begin p 39
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b049">49</xref>
###xml 521 523 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b050">50</xref>
Pairwise crude comparisons of lipid levels and lipid particle sizes among the study groups were carried out using the Mann-Whitney U-test because the distributions were skewed. Calculations were carried out using SAS version 6.12 (SAS Institute, Cary, North Carolina, United States) and Stata version 8.2SE (StataCorp, College Station, Texas, United States). Analyses of lipid parameters were stratified by sex, given that there are known differences between female and male lipid profiles and cardiovascular risks [ 49, 50]. Results are expressed as mean (SE).
###end p 39
###begin p 40
###xml 114 122 114 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="st001">Table S1</xref>
###xml 220 221 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
In order to take into consideration the false positive associations resulting from multiple tests of the 66 SNP ( Table S1), a Bonferroni correction was applied to determine the proper level of statistical significance, p = 0.05/66 = 0.0007.
###end p 40
###begin p 41
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 223 224 223 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0040113-b051">51</xref>
For a comparison of the difference in APOC3 C(-641)A genotype frequencies between the groups, the chi-square test was performed. Genotype frequencies of all SNP were found to be in Hardy-Weinberg equilibrium. A (corrected) p-value less than 0.05 was considered the threshold for statistical significance. Given that this is a relatively homogeneous population, stratification was not applied, except to control for gender effects as noted above. The haplotype association test between cases (probands) and controls was performed using Haploview 3.2 software ( ) [ 51].
###end p 41
###begin p 42
###xml 4 16 <span type="species:ncbi:9606">participants</span>
The participants' survival distribution was estimated by the Kaplan-Meier method, and the significance of the difference in survival distribution among the groups was tested by means of a log rank test. Wilcoxon statistics were calculated to test homogeneity between the groups.
###end p 42
###begin title 43
Supporting Information
###end title 43
###begin title 44
Genes and Their Associated SNP Genotyped for This Study
###end title 44
###begin p 45
###xml 88 89 88 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
The reported values are percent in Control/Proband and its significance of the change ( p-Value).
###end p 45
###begin p 46
###xml 33 40 33 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP-VV</italic>
###xml 45 54 45 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC-3 CC</italic>
###xml 76 77 76 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
After Bonferroni correction only CETP-VV and APOC-3 CC remain significant ( p < 0.0066).
###end p 46
###begin p 47
(135 KB DOC)
###end p 47
###begin p 48
Click here for additional data file.
###end p 48
###begin p 49
###xml 116 128 <span type="species:ncbi:9606">participants</span>
We thank Mr. William Greiner and Ms. Deborah Davidson for their contributions to this study. We are indebted to all participants and their families for their commitment and enthusiasm. We are also grateful to the following institutions that assisted in recruitment: The Hebrew Home for the Aged, Riverdale, New York; Kittay House, Bronx, New York; the Hebrew Home and Hospital, West Hartford, Connecticut; and the Jewish Home for the Aged, New Haven, Connecticut, all under the aegis of the Association of Jewish Aging Services of North America, Washington, D. C.
###end p 49
###begin p 50
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 50
###begin p 51
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. This work has been supported by grants from the Paul Beeson Physician Faculty Scholar in Aging Award, the Ellison Medical Foundation Senior Scholar Award, NIH RO1 (AG-18728-01A1), the General Clinical Research Center (NIH M01-RR12248), and Diabetes Research and Training Center (NIH DK 20541) at the Albert Einstein College of Medicine, and the Baltimore VA Geriatric Research and Education Clinical Center.
###end p 51
###begin title 52
References
###end title 52
###begin article-title 53
If you would live long, choose your parents well
###end article-title 53
###begin article-title 54
Life-long sustained mortality advantage of siblings of centenarians
###end article-title 54
###begin article-title 55
Siblings of centenarians live longer
###end article-title 55
###begin article-title 56
###xml 14 19 <span type="species:ncbi:9606">human</span>
Searching for human longevity genes: The future history of gerontology in the post-genomic era
###end article-title 56
###begin article-title 57
Clinical phenotype of Families with longevity
###end article-title 57
###begin article-title 58
Unique lipoprotein phenotype and genotype associated with exceptional longevity
###end article-title 58
###begin article-title 59
###xml 91 96 <span type="species:ncbi:9606">human</span>
Haplotype-based identification of a microsomal transfer protein marker associated with the human lifespan
###end article-title 59
###begin article-title 60
The apoAI-CIII-AIV gene cluster
###end article-title 60
###begin article-title 61
###xml 52 57 <span type="species:ncbi:9606">human</span>
Banting lecture 1988. Role of insulin resistance in human disease
###end article-title 61
###begin article-title 62
###xml 130 133 <span type="species:ncbi:9606">man</span>
Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
###end article-title 62
###begin article-title 63
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report
###end article-title 63
###begin article-title 64
Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III
###end article-title 64
###begin article-title 65
Apolipoprotein C3 SstI polymorphism in the risk assessment of CAD
###end article-title 65
###begin article-title 66
Influence of the APOC3 -2854T>G polymorphism on plasma lipid levels: Effect of age and gender
###end article-title 66
###begin article-title 67
Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: The Framingham offspring study
###end article-title 67
###begin article-title 68
###xml 114 121 <span type="species:ncbi:4097">tobacco</span>
Associations of LPL and APOC3 gene polymorphisms on plasma lipids in a Mediterranean population: Interaction with tobacco smoking and the APOE locus
###end article-title 68
###begin article-title 69
Association of Sst I polymorphism in apolipoprotein C3 gene with hypertriglyceridaemia in coronary atherosclerotic heart disease and type II diabetes mellitus in Chinese population
###end article-title 69
###begin article-title 70
###xml 64 67 <span type="species:ncbi:9606">men</span>
Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders
###end article-title 70
###begin article-title 71
Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease
###end article-title 71
###begin article-title 72
Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes
###end article-title 72
###begin article-title 73
Genetic effect of two polymorphisms in the apolipoprotein A5 gene and apolipoprotein C3 gene on serum lipids and lipoproteins levels in a Chinese population
###end article-title 73
###begin article-title 74
###xml 127 135 <span type="species:ncbi:9606">Patients</span>
Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and "insulin-resistant" T-455C APOC3 gene polymorphism in heart Disease Patients: Example of gene-diet interaction
###end article-title 74
###begin article-title 75
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 70 85 <span type="species:ncbi:10090">transgenic mice</span>
Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice
###end article-title 75
###begin article-title 76
###xml 56 60 <span type="species:ncbi:10090">mice</span>
Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia
###end article-title 76
###begin article-title 77
###xml 115 119 <span type="species:ncbi:10090">mice</span>
Apolipoprotein CIII deficiency prevents the development of hypertriglyceridemia in streptozotocin-induced diabetic mice
###end article-title 77
###begin article-title 78
###xml 56 61 <span type="species:ncbi:9606">human</span>
Apolipoprotein multigene family: Tandem organization of human apolipoprotein AI, CIII, and AIV genes
###end article-title 78
###begin article-title 79
###xml 66 72 <span type="species:ncbi:9606">people</span>
The study of APOA1, APOC3 and APOA4 variability in healthy ageing people reveals another paradox in the oldest old subjects
###end article-title 79
###begin article-title 80
###xml 29 34 <span type="species:ncbi:9606">human</span>
Vascular genetic factors and human longevity
###end article-title 80
###begin article-title 81
Genetic heterogeneity in the apolipoprotein C-III promoter and effects of insulin
###end article-title 81
###begin article-title 82
###xml 48 53 <span type="species:ncbi:9606">human</span>
Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia
###end article-title 82
###begin article-title 83
Deficiency of choresteryl ester transfer protein and gene polymorphisms of lipoprotein lipase and hepatic lipase are not associated with longevity
###end article-title 83
###begin article-title 84
[I405V polymorphism of the cholesteryl ester transfer protein gene in young and very old individuals]
###end article-title 84
###begin article-title 85
###xml 65 87 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans
###end article-title 85
###begin article-title 86
###xml 72 76 <span type="species:ncbi:10090">mice</span>
IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice
###end article-title 86
###begin article-title 87
A conserved regulatory system for aging
###end article-title 87
###begin article-title 88
###xml 95 104 <span type="species:ncbi:7460">honeybees</span>
Hormonal control of the yolk precursor vitellogenin regulates immune function and longevity in honeybees
###end article-title 88
###begin article-title 89
The paradox of the insulin/IGF-1 signaling pathway in longevity
###end article-title 89
###begin article-title 90
Foxo1 mediates insulin action on apoC-III and triglyceride metabolism
###end article-title 90
###begin article-title 91
A Genetic Profile of Contemporary Jewish Populations
###end article-title 91
###begin article-title 92
The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
###end article-title 92
###begin article-title 93
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome
###end article-title 93
###begin article-title 94
Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families
###end article-title 94
###begin article-title 95
A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers
###end article-title 95
###begin article-title 96
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
###end article-title 96
###begin article-title 97
###xml 144 152 <span type="species:ncbi:9606">patients</span>
###xml 169 174 <span type="species:ncbi:9606">women</span>
The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women
###end article-title 97
###begin article-title 98
A common Lithuanian mutation causing familial hypercholesterolemia in Ashkenazi Jews
###end article-title 98
###begin article-title 99
Leisure activities and the risk of dementia in the elderly
###end article-title 99
###begin article-title 100
A multilocus genotyping assay for candidate markers of cardiovascular disease risk
###end article-title 100
###begin article-title 101
HDL particle size: A marker of the gender difference in the metabolic risk profile
###end article-title 101
###begin article-title 102
Risk factors and the sex differential in coronary artery disease
###end article-title 102
###begin article-title 103
Haploview: Analysis and visualization of LD and haplotype maps
###end article-title 103
###begin title 104
Abbreviations
###end title 104
###begin p 105
apolipoprotein A-1
###end p 105
###begin p 106
apolipoprotein A4 gene
###end p 106
###begin p 107
apolipoprotein C3
###end p 107
###begin p 108
apolipoprotein C3 gene
###end p 108
###begin p 109
cholesterol ester transfer protein gene
###end p 109
###begin p 110
coefficient of variance
###end p 110
###begin p 111
cardiovascular disease
###end p 111
###begin p 112
diabetes mellitus
###end p 112
###begin p 113
high density lipoprotein cholesterol
###end p 113
###begin p 114
linkage disequalibrium
###end p 114
###begin p 115
low density lipoprotein cholesterol
###end p 115
###begin p 116
single nucleotide polymorphisms
###end p 116
###begin p 117
triglycerides
###end p 117
###begin p 118
valine-valine
###end p 118
###begin title 119
Figures and Tables
###end title 119
###begin title 120
###xml 50 63 50 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3, APOA4,</italic>
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP</italic>
Distribution of "Favorable" Gene Polymorphisms of APOC3, APOA4, and CETP in the Study Population
###end title 120
###begin p 121
###xml 64 72 64 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3 C(</italic>
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">641)A</italic>
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP</italic>
###xml 424 429 424 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 441 446 441 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA4</italic>
###xml 459 464 459 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA4</italic>
The genotype frequencies of the favorable gene polymorphisms of APOC3 C(- 641)A and CETP I405V were analyzed in controls and probands (60 to 100 y old). (Offspring were not included in this analysis due to the genotype dependency of this group on proband genotypes.) The frequency of these two variants was found to be higher among centenarians, with a monotonic increase with age. Other polymorphisms in these same genes ( APOC3 (-455) TT, APOA4 347 TT, and APOA4 360 EE) showed no differences in genotype frequency with age.
###end p 121
###begin title 122
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA4</italic>
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP</italic>
Haplotype Structure of APOC3 and APOA4 and CETP
###end title 122
###begin p 123
Ordinal arrangement of 15 SNP associated with CVD and lipoprotein metabolism, according to their position on chromosomes with LD (number in boxes) where the highest rate is represented in red and no LD in lilac. Blocks define potential haplotypes between two clustered genes.
###end p 123
###begin p 124
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA4.</italic>
(A) APOC3 and APOA4.
###end p 124
###begin p 125
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP.</italic>
(B) CETP.
###end p 125
###begin title 126
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
Genotype Distribution of APOC3 C(-641)A and Serum APOC3 Concentrations
###end title 126
###begin p 127
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
(A) APOC3 C(-641)A.
###end p 127
###begin p 128
(B) Serum APOC3.
###end p 128
###begin p 129
###xml 2 3 2 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 15 16 15 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
* p < 0.05, ** p = 0.001 versus control.
###end p 129
###begin p 130
CC, homozygous for (-641) C; AA, homozygous for (-641) A; CA, heterozygous for (-641) C/A.
###end p 130
###begin title 131
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
Insulin Sensitivity and Hypertension according to APOC3 C(-641)A Genotype
###end title 131
###begin p 132
All include offspring plus controls.
###end p 132
###begin p 133
(A) Insulin sensitivity.
###end p 133
###begin p 134
(B) Hypertension.
###end p 134
###begin p 135
###xml 2 3 2 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
* p = 0.05
###end p 135
###begin p 136
CC, homozygous for (-641) C; CA/AA, homozygous and heterozygous for (-641) A.
###end p 136
###begin title 137
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
Survival Analysis according to APOC3 Genotypes
###end title 137
###begin p 138
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 11 23 <span type="species:ncbi:9606">participants</span>
###xml 288 300 <span type="species:ncbi:9606">participants</span>
Of the 381 participants we genotyped since 1998, 64 had the -641 CC genotype. To describe the relationship between genotype and death, we plotted the Kaplan-Meier survival function estimates of probands and controls by APOC3 genotype. Offspring were excluded in this analysis because all participants are currently alive and offspring genotype/phenotype is not independent of the probands.
###end p 138
###begin p 139
###xml 11 12 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 35 36 35 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Log-Rank ( p = 0.0008); Wilcoxon ( p = 0.0007).
###end p 139
###begin p 140
CC, homozygous for (-641) C; CA/AA, homozygous and heterozygous for (-641) A.
###end p 140
###begin p 141
###xml 139 144 139 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
Comparison of Lipoprotein Traits in Females, Males, and All (Combined Offspring and Control Group) Who Were Not on Lipid-Lowering Drugs by APOC3 C(-641)A Genotype
###end p 141
###begin p 142
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. NB conceived and designed the experiments. GA, MR, and NB performed the experiments. GA, CBS, ARS, RBL, AB, and NB analyzed the data. GA, MR, CBS, ARS, RBL, AB, and NB contributed reagents/materials/analysis tools. GA, MR, CBS, ARS, RBL, AB, and NB wrote the paper.
###end p 142
###begin p 143
###xml 155 161 <span type="species:ncbi:9606">humans</span>
Citation: Atzmon G, Rincon M, Schechter CB, Shuldiner AR, Lipton RB, et al. (2006) Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS Biol 4(4): e113.
###end p 143

